Detalhe da pesquisa
1.
JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analog suppressed patients with chronic hepatitis B: REEF-2.
J Hepatol
; 2024 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38583491
2.
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection.
Gut
; 72(7): 1385-1398, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36697207
3.
Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB.
J Hepatol
; 77(5): 1287-1298, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35870702
4.
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1.
Hepatology
; 69(6): 2349-2363, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30693573
5.
Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications.
Br J Clin Pharmacol
; 84(5): 961-971, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29345798
6.
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study.
Hepatology
; 64(2): 370-80, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26799692
7.
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).
Hepatology
; 64(2): 360-9, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26704148
8.
Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.
BMC Infect Dis
; 17(1): 389, 2017 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28577353
9.
Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.
Transpl Infect Dis
; 19(3)2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28295849
10.
Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.
J Gastroenterol Hepatol
; 31(5): 912-20, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26777137
11.
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet
; 384(9941): 414-26, 2014 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-24907224
12.
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet
; 384(9941): 403-13, 2014 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-24907225
13.
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.
Gastroenterology
; 146(7): 1669-79.e3, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24602923
14.
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
Lancet Gastroenterol Hepatol
; 8(9): 790-802, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37442152
15.
Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor.
J Med Chem
; 57(5): 1673-93, 2014 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24446688